Firefly Neuroscience (AIFF) Common Equity (2010 - 2026)

Firefly Neuroscience's Common Equity history runs 17 years deep, the most recent figure standing at $8.4 million for Q1 2026.

• In Q1 2026, Common Equity rose 62.82% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (up 62.82% YoY), while the FY2025 annual figure was $7.6 million, up 2136.53% from the prior year.
• Common Equity was $8.4 million for Q1 2026 at Firefly Neuroscience, up from $7.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $15.7 million in Q1 2022 to a low of -$2.8 million in Q3 2024.
• Historically, Common Equity has averaged $4.7 million across 5 years, with a median of $2.4 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Common Equity plunged 444.04% in 2024, then surged 57711.11% in 2025.
• A 5-year view of Common Equity shows it stood at -$2.2 million in 2022, then jumped by 104.9% to $109000.0 in 2023, then slumped by 444.04% to -$375000.0 in 2024, then surged by 2136.53% to $7.6 million in 2025, then increased by 10.54% to $8.4 million in 2026.
• The last three Common Equity figures came in at $8.4 million (Q1 2026), $7.6 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.